prikaz prve stranice dokumenta Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim
Rad je dostupan svim korisnicima iz sustava znanosti i visokog obrazovanja RH
Znanstveni rad - Izvorni znanstveni rad
Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim
Transfusion and Apheresis Science, (2022); 103582. https://doi.org/10.1016/j.transci.2022.103582
Krečak, Ivan; Skorić, Ivana; Čengić, Marina; Krečak, Filip; Skelin, Marko

Citirajte ovaj rad

Krečak, I., Skorić, I., Čengić, M., Krečak, F. i Skelin, M. (2022). Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim. Transfusion and Apheresis Science. doi: 10.1016/j.transci.2022.103582

Krečak, Ivan, et al. "Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim." Transfusion and Apheresis Science, 2022. https://doi.org/10.1016/j.transci.2022.103582

Krečak, Ivan, Ivana Skorić, Marina Čengić, Filip Krečak i Marko Skelin. "Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim." Transfusion and Apheresis Science (2022). https://doi.org/10.1016/j.transci.2022.103582

Krečak, I., et al. (2022) 'Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim', Transfusion and Apheresis Science. doi: 10.1016/j.transci.2022.103582

Krečak I, Skorić I, Čengić M, Krečak F, Skelin M. Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim. Transfusion and Apheresis Science [Internet]. 10.2022. [pristupljeno 03.12.2024.]. doi: 10.1016/j.transci.2022.103582

I. Krečak, I. Skorić, M. Čengić, F. Krečak i M. Skelin, "Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim", Transfusion and Apheresis Science, Listopad 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:541304. [Citirano: 03.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:541304
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim
AutorIvan Krečak
AutorIvana Skorić
AutorMarina Čengić
AutorFilip Krečak
AutorMarko Skelin
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Immune-mediated platelet transfusion refractoriness due to anti-human leukocyte antigen (HLA) antibodies can occur in approximately 9% of patients with myelodysplastic syndromes (MDS) and can lead to an increased risk of clinically relevant bleeds and treatment delays. These patients are typically managed with frequent platelet transfusions; however, HLA-matched platelet transfusions are usually available only in large blood centers. For this reason, alloimunized thrombocytopenic MDS patients are notoriously difficult to manage. Here, we present a case of a MDS patient with an immune-mediated platelet transfusion refractoriness, severe thrombocytopenia and spontaneous subarachnoid hemorhage who we successfully treated with romiplostim, a thrombopoietin receptor agonist.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objavePrihvaćen za objavljivanje
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaTransfusion and Apheresis Science
Brojčani podaci103582
p-ISSN1473-0502
DOIhttps://doi.org/10.1016/j.transci.2022.103582
URN:NBNurn:nbn:hr:184:541304
Datum objave publikacije2022-10
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S1473050222002816
Vrsta resursaTekst
Prava pristupaOgraničen pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-11-14 07:23:10